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Abstract
Objective(s): To determine if mishandling prior to testing would make a sample from a chronically infected subject appear
recently infected when tested by cross-sectional HIV incidence assays.
Methods: Serum samples from 31 subjects with chronic HIV infection were tested. Samples were subjected to different
handling conditions, including incubation at 4uC, 25uC and 37uC, for 1, 3, 7 or 15 days prior to testing. Samples were also
subjected to 1,3, 7 and 15 freeze-thaw cycles prior to testing. Samples were tested using the BED capture enzyme immuno
assay (BED-CEIA), Vironostika-less sensitive (V-LS), and an avidity assay using the Genetic Systems HIV-1/HIV-2 plus O EIA
(avidity assay).
Results: Compared to the sample that was not subjected to any mishandling conditions, for the BED-CEIA, V-LS and avidity
assay, there was no significant change in test results for samples incubated at 4uCo r2 5 uC prior to testing. No impact on test
results occurred after 15 freeze-thaw cycles. A decrease in assay results was observed when samples were held for 3 days or
longer at 37uC prior to testing.
Conclusions: Samples can be subjected up to 15 freeze-thaw cycles without affecting the results the BED-CEIA, Vironostika-
LS, or avidity assays. Storing samples at 4uCo r2 5 uC for up to fifteen days prior to testing had no impact on test results.
However, storing samples at 37uC for three or more days did affect results obtained with these assays.
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Introduction
Accurate estimates of HIV-1 incidence are needed to evaluate
the state of the HIV epidemic, to calibrate and validate models of
epidemiology, and to plan and assess the impact of prevention
interventions [1,2]. Incidence testing provides a measure of the
recent level of HIV-1 transmission in a population [2]. To obtain
HIV-1 incidence estimates from cross-sectional cohorts, testing
methods have been developed that take advantage of the biological
differences between recently-infected and chronically-infected
individuals [3,4]. Three assays used to estimate the proportion
of recently-infected individuals in a population are the BED
capture enzyme immuno assay (BED-CEIA) [5], the Vironostika-
less sensitive assay (V-LS) [6], and assays based on antibody avidity
[7,8,9]. However, it is not known how serum/plasma sample
handling conditions impact data generated by these incidence
assays. Because incidence assays are most often performed using
stored samples that may have been freeze-thawed for other
investigations, it is critical to understand how prior storage and
manipulation of samples might affect the data generated by cross-
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25899sectional incidence assays. We evaluated the impact of sample
storage (4uC, 25uC and 37uC for up to two weeks) and freeze-thaw
cycles (up to 15 cycles) on results obtained with the BED-CEIA, V-
LS, and avidity assays.
Methods
Samples
Samples from 31 individuals with known chronic HIV infection
were examined. All individuals had been HIV-infected for more
than two years prior to sample collection, were not on
antiretroviral drug therapy, had viral loads $10,000 copies/ml
and had CD4 cell counts $200 cells/ml (range 209 to 1293). Six
samples were from South African women (subtype-C), and eight
samples from Ugandan women (two subtype A and six subtype D).
Samples from these African study subjects were described in a
previous report [10]. The remaining 17 samples were from adult
patients at the Moore Clinic at Johns Hopkins University in
Baltimore (subtype B). All work was conducted in accordance with
the Declaration of Helsinki. All samples were delinked from
personal identifiers. All participants provided written informed
consent.The study was approved by the Institutional Review
Boards of the Johns Hopkins University, Witwatersrand University
and the Science Ethics Committee of the Uganda Virus Research
Institute.
Testing conditions
An approximate initial 1.3 ml aliquot (range 1.0 to 1.8 ml) of
stored serum that had not been used for other purposes was tested.
Samples were initially dispensed into as many 100 ml aliquots as
the initial sample volume allowed. A control aliquot from each
individual was stored at 280uC without further manipulation. The
remaining aliquots from each individual were systematically
subjected either to freeze-thaw cycles (3, 7, or 15 freeze-thaw
cycles), or incubation at 4uC, 25uCo r3 7 uC for specific times (1, 3,
7, or 15 days). After each manipulation, the samples were stored at
280uC until incidence testing was performed. To avoid run-to-run
variation, all aliquots from a given individual were tested within
the same run.
HIV incidence testing
The BED-CEIA assay was performed according to the
manufacturer’s protocol (Calypte Biomedical Corporation, Lake
Oswego, OR, USA) [5]. The V-LS assay was performed using a
standardized optical density (SOD) cut-off of 1.0 with a 1:20,000
diluted sera, as previously described [6]. The avidity assay was
performed using the Genetic Systems HIV-1/HIV-2 Plus O EIA
(Bio-Rad Laboratories, Redmond, WA) [9,11]. To test antibody
avidity samples were diluted 1:10, incubated at 4uC for 30 minutes
for the initial antibody-binding step, and then incubated with
0.1 M diethylamine for 30 minutes at 37uC for the chaotropic
disassociation step. The percent avidity (Avidity Index, AI) was
calculated for each sample. The AI was calculated by dividing the
optical density of the DEA treated well by the optical density of the
non-treated well for the same sample and multiplying by 100. All
testing was performed at Johns Hopkins University.
Analysis of HIV incidence testing data
For each study subject, we compared results from each of the
three assays using the control aliquot and aliquots that were
subjected to each type of freeze-thaw or storage manipulation.
Paired t-tests were used to determine whether there was a
significant change from the control aliquot for each type of
manipulation. Statistical analyses were performed using Stata
version 10.1.
Results
A total of 428, 381 and 376 samples from the original 31
chronically infected patients were tested using BED-CEIA, V-LS,
and avidity assays, respectively. Total samples available for each
test differed because of the difference in the initial sample volumes
available. For the BED-CEIA, the median normalized optical
density (OD-n) of the untreated samples was 3.05 (interquartile
Table 1. Mean Change in Assay Results by Handling Condition.
Days incubated prior to testing 1371 5
N Mean Change (SD) N Mean Change (SD) N Mean Change (SD) N Mean Change (SD)
BED assay (OD-n)
Storage at 4uC3 0 20.05 (60.59) 31 20.01 (60.23) 31 0.02 (60.26) 27 20.01 (60.31)
Storage at 25uC 30 0.02 (60.25) 32 20.03 (60.22) 31 20.02 (60.12) 27 20.05 (60.23)
Storage at 37uC3 1 20.02 (60.21) 28 20.19 (60.29){ 19 20.34 (60.27){ 6 20.54 (60.20){
Vironostika-LS assay (SOD)
Storage at 4uC 31 0.08 (60.33) 31 0.01 (60.45) 31 0.05(60.54) 8 0.11 (60.58)
Storage at 25uC 30 0.13 (60.41) 31 0.06 (60.40) 30 0.07(60.50) 8 20.16 (60.36)
Storage at 37uC 30 0.02(60.45) 28 20.21 (60.50){ 19 20.71 (61.33){ 3 20.96 (60.33){
Avidity assay (%)
Storage at 4uC 31 1.71 (65.67) 31 0.36 (68.17) 30 21.75 (618.9) 8 23.41 (610.0)
Storage at 25uC3 1 20.29 (67.20) 31 0.89 (64.71) 30 23.38 (619.1) 8 22.54 (68.32)
Storage at 37uC3 1 20.34 (64.98) 28 21.41 (64.90) 14 27.71 (618.0) 3 21.99 (61.04)+
SD: Standard Deviation. Paired t-test: {p,.05, {p,.01, +p = .08
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value for untreated samples was 4.54 (IQR: 3.67, 5.19). Samples
tested using the avidity assay had a baseline median percent
avidity (AI) of 100% (IQR: 78.7%, 100.0%).
Results from the BED-CEIA, V-LS, and avidity assays are
shown in Table 1 and Figures S1, S2, S3, S4, S5, S6, S7, S8 and
S9. The impact of freeze thaw cycles on testing is shown in Table 2
and Figures S10, S11, and S12. With the exception of conditions
in which samples were stored at 37uC, there were no significant
differences in results obtained using the control vs. manipulated
samples. For samples stored at 37uC a decrease in testing values
was observed using the BED-CEIA and V-LS assays. The mean
decrease in OD-n for the BED-CEIA was 0.19 for 3 days, 0.34 for
7 days and 0.54 for 15 days. A similar trend was seen with the V-
LS assay as the SOD values changed when the samples were
incubated at 37uC prior to testing, with a mean decrease of 0.21
for 3 days, 0.71 for 7 days and 0.96 for 15 days. For the avidity
assay, a nonsignificant decrease in AI was seen for samples
incubated at 37uC prior to testing, with a mean decrease 1.41 for 3
days, 7.71 for 7 days and 1.99 for 15 days.
Discussion
Our analysis demonstrates that results generated using the BED-
CEIA, V-LS, and avidity assays are not significantly affected by
most sample-handing conditions. Freezing and thawing samples up
to 15 times had no impact on the values generated by any of the
three assays. Additionally, storing samples at 4uCo r2 5 uC prior to
testing had no statistically significant effect on the test results in the
bivariate analyses. We did demonstrate a minor decrease in the
values obtained using the BED-CEIA, V-LS, and avidity assays
when samples were stored for an extended period at 37uC. Because
relatively few aliquots were tested in the evaluation of the 15-day
incubation and 15 freeze-thaw cycle conditions, the moderate
changes observed in assay test results under those conditions were
not conclusive. A larger sample size might provide stronger
statistical support. These results are similar to those reported
previously for the stability of samples used for testing with HIV-1
antibody assays for the diagnosis of HIV-1 infection [12]. In that
study, repeated freeze-thaws and incubation at 220uCa n d4 uC did
not alter the capacity of ELISA and Western blot assays to detect
antibodies to HIV. A small decline in antibody reactivity was noted
when samples were incubated at 25uCo r3 7 uC for more than 21
days;however,thatchangedidnot alterthe interpretation ofthetest
results. [12]. Our study extends the previous study by evaluating the
effect of freeze-thaws and incubation at different temperatures on
the performance of assays that measure different characteristics of
the anti-HIV antibody response: the proportion of antibody that is
HIV-specific, antibody titer, and antibody avidity. In summary,
these data indicate that stored samples previously frozen and
thawed multiple times can be used for antibody-based incidence
testing. Unless samples were stored at excessive temperatures for an
extended period, similar results were obtained using samples
subjected to a variety of freeze-thaw and incubation conditions.
Supporting Information
Figure S1 Effect of Days at 46C on BED-CEIA Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was incubated
at 4uC prior to testing. The y-axis is the assay results in normalized
optical density units.
(PDF)
Figure S2 Effect of Days at 256C on BED-CEIA Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was incubated
at 25uC prior to testing. The y-axis is the assay results in
normalized optical density units.
(PDF)
Figure S3 Effect of Days at 376C on BED-CEIA Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was incubated
at 37uC prior to testing. The y-axis is the assay results in
normalized optical density units.
(PDF)
Figure S4 Effect of Days at 46C on Vironostika-LS Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was incubated
at 4uC prior to testing. The y-axis is the assay results in
standardized optical density units.
(PDF)
Table 2. Mean Change in Assay Results by Number of Freeze Thaw Cycles Prior to Testing.
Number of freeze thaw cycles prior to testing 37 1 5
N Mean Change (SD) N Mean Change (SD) N Mean Change (SD)
BED assay (OD-n) 31 20.04 (60.23) 30 20.01 (60.23) 12 20.01 (60.23)
Vironostika-LS assay (SOD) 31 0.02 (60.41) 31 20.01 (60.42) 8 20.05 (60.50)
Avidity assay (%) 31 1.39 (67.48) 30 1.86 (65.84) 8 24.02 (612.7)
SD: Standard Deviation.
Mean Change in Assay Results by Number of Freeze Thaw Cycles Prior to Testing.
SD: standard deviation; OD-n: normalized optical density; SOD standardized optical density.
doi:10.1371/journal.pone.0025899.t002
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Assay Results. Samples from subtype C infected individuals
from South Africa are marked in green. Samples from subtype A
infected individuals from Uganda are marked in orange. Samples
from subtype D infected individuals from Uganda are marked in
red. Samples from subtype B infected individuals are marked in
blue. The x-axis denotes the number of days the sample was
incubated at 25uC prior to testing. The y-axis is the assay results in
standardized optical density units.
(PDF)
Figure S6 Effect of Days at 376C on Vironostika -LS
Assay. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was incubated
at 37uC prior to testing. The y-axis is the assay results in
standardized optical density units.
(PDF)
Figure S7 Effect of Days at 46C on Avidity Assay
Results. Samples from subtype C infected individuals from
South Africa are marked in green. Samples from subtype A
infected individuals from Uganda are marked in orange. Samples
from subtype D infected individuals from Uganda are marked in
red. Samples from subtype B infected individuals are marked in
blue. The x-axis denotes the number of days the sample was
incubated at 4uC prior to testing. The y-axis is the assay results as
an avidity index.
(PDF)
Figure S8 Effect of Days at 256C on Avidity Assay
Results. Samples from subtype C infected individuals from
South Africa are marked in green. Samples from subtype A
infected individuals from Uganda are marked in orange. Samples
from subtype D infected individuals from Uganda are marked in
red. Samples from subtype B infected individuals are marked in
blue. The x-axis denotes the number of days the sample was
incubated at 25uC prior to testing. The y-axis is the assay results as
an avidity index.
(PDF)
Figure S9 Effect of Days at 376C on Avidity Assay
Results. Samples from subtype C infected individuals from
South Africa are marked in green. Samples from subtype A
infected individuals from Uganda are marked in orange. Samples
from subtype D infected individuals from Uganda are marked in
red. Samples from subtype B infected individuals are marked in
blue. The x-axis denotes the number of days the sample was
incubated at 37uC prior to testing. The y-axis is the assay results as
an avidity index.
(PDF)
Figure S10 Freeze Thaw Cycles on BED-CEIA Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number of days the sample was freeze
thawed prior to testing. The y-axis is the assay results in
normalized optical density units.
(PDF)
Figure S11 Freeze Thaw Cycles on Vironostika-LS Assay
Results. Samples from subtype C infected individuals from South
Africa are marked in green. Samples from subtype A infected
individuals from Uganda are marked in orange. Samples from
subtype D infected individuals from Uganda are marked in red.
Samples from subtype B infected individuals are marked in blue.
The x-axis denotes the number times the sample was freeze
thawed prior to testing. The y-axis is the assay results in
standardized optical density units.
(PDF)
Figure S12 Effect of Freeze Thaw Cycles on Avidity
Assay Results. Samples from subtype C infected individuals
from South Africa are marked in green. Samples from subtype A
infected individuals from Uganda are marked in orange. Samples
from subtype D infected individuals from Uganda are marked in
red. Samples from subtype B infected individuals are marked in
blue. The x-axis denotes the number of days the sample was freeze
thawed prior to testing prior to testing. The y-axis is the assay
results as an avidity index.
(PDF)
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